购物车
全部删除
您的购物车当前为空
GSK 366 is a potent kynurenine-3-monooxygenase (KMO) inhibitor (IC50s: 0.7 nM and 2.3 nM for P. fluorescens-KMO and human KMO).

GSK 366 is a potent kynurenine-3-monooxygenase (KMO) inhibitor (IC50s: 0.7 nM and 2.3 nM for P. fluorescens-KMO and human KMO).
| 规格 | 价格 | 库存 | 数量 |
|---|---|---|---|
| 25 mg | 待询 | 3-6月 | |
| 50 mg | 待询 | 3-6月 | |
| 100 mg | 待询 | 3-6月 |
| 产品描述 | GSK 366 is a potent kynurenine-3-monooxygenase (KMO) inhibitor (IC50s: 0.7 nM and 2.3 nM for P. fluorescens-KMO and human KMO). |
| 靶点活性 | PfKMO:0.7 nM , KMO (human):2.3 nM |
| 分子量 | 361.78 |
| 分子式 | C17H16ClN3O4 |
| CAS No. | 1953157-39-5 |
| 密度 | 1.390 g/cm3 (Predicted) |
| 存储 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| 溶解度信息 | DMSO: 250 mg/mL (691.03 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
| 体内实验配方 | 10% DMSO+40% PEG300+5% Tween-80+45% Saline: 3.3 mg/mL (9.12 mM), Sonication is recommeded. 请按顺序添加溶剂,在添加下一种溶剂之前,尽可能使溶液澄清。如有必要,可通过加热、超声、涡旋处理进行溶解。工作液建议现配现用。以上配方仅供参考,体内配方并不是绝对的,请根据不同情况进行调整。 | |||||||||||||||||||||||||||||||||||
溶液配制表 | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||
以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。
对于不同动物的给药剂量换算,您也可以参考 更多